Showing 1 - 20 results of 1,173 for search '(( third ((((larger decrease) OR (a decrease))) OR (mean decrease)) ) OR ( non small decrease ))', query time: 0.49s Refine Results
  1. 1

    DataSheet1_Decreasing viscosity and increasing accessible load by replacing classical diluents with a hydrotrope in liquid–liquid extraction.docx by Asmae El Maangar (19690522)

    Published 2025
    “…We show that using hydrotropes as a diluent decreases the viscosity of solutions by more than a factor of ten, even under high load by extracted cations. …”
  2. 2
  3. 3

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  4. 4
  5. 5
  6. 6

    Fluctuation trend of the mean temperature index. by Chengyuan Hao (21615653)

    Published 2025
    “…Secondly, the daily minimum and maximum temperatures increased significantly, which were 0.395°C/10a and 0.200°C/10a respectively<b>—</b>less than the national mean. …”
  7. 7

    Variation curve of the mean temperature index. by Chengyuan Hao (21615653)

    Published 2025
    “…Secondly, the daily minimum and maximum temperatures increased significantly, which were 0.395°C/10a and 0.200°C/10a respectively<b>—</b>less than the national mean. …”
  8. 8

    Mann-Kendall test for the mean temperature index. by Chengyuan Hao (21615653)

    Published 2025
    “…Secondly, the daily minimum and maximum temperatures increased significantly, which were 0.395°C/10a and 0.200°C/10a respectively<b>—</b>less than the national mean. …”
  9. 9
  10. 10
  11. 11
  12. 12

    Data Sheet 1_Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic N... by Xinhang Gu (22686224)

    Published 2025
    “…Background<p>Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-based combination therapy modalities for patients with EGFR-mutated stage IV non-small cell lung cancer (NSCLC) are being investigated. …”
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20